Definitive Contract 75N93019C00009
Award Date 5/31/19
Potential Completion Date 11/30/20
Potential Value $300K
Federal Agency
Awardee
Ultimate Awardee
Not listed NAICS Category
Federal Contract Vehicle
- Not listed
Set-Aside Type
Total Small Business
Extent Competed
Full and Open Competition after exclusion of sources
Major Defense Program
Not listed Pricing Type
Firm Fixed Price
Place of Performance
Pottstown, PA 19464, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
2
Legislative Mandate
Not listed National Interest Action
Not listed Research Type
SBIR Program Phase I Action
Primary Consortia Member
Not listed Similar Awards
- This contract was awarded to Abzyme Therapeutics LLC, a small business, by the Joint PEO Chemical and Biological Defense, which is a defense agency. The contract is a Small Business Innovation Research (SBIR) Program Phase I award with a firm fixed price of $149,656.59 and a period of performance through January 13, 2018. The contract is focused on research and development services related to enhancing HIV gp120 protein production using camelid VHH antibodies. Abzyme Therapeutics LLC is a...
- This federal contract award, valued at $149,964.61, was made by the Joint Program Executive Office for Chemical and Biological Defense, a U.S. Department of Defense organization, to Abzyme Therapeutics LLC, a small, minority-owned, for-profit limited liability company. The contract was awarded under the Small Business Innovation Research (SBIR) program, Phase I, and is a firm-fixed-price purchase order. The contract supports research and development work by Abzyme Therapeutics related to...
- This is a Small Business Innovation Research (SBIR) Phase II contract awarded by the Department of the Army Acquisition Support Center Joint PEO Chemical and Biological Defense to Abzyme Therapeutics LLC, a minority-owned biopharmaceutical company. The contract, valued at $999,998.10, is for research and development services related to enhancing HIV gp120 protein production using camelid VHH antibodies. The contract is a Firm Fixed Price Definitive Contract, and the place of performance is...
- This is a $300,000.00 firm-fixed-price Small Business Innovation Research (SBIR) Phase I contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), part of the U.S. Department of Health and Human Services, to Cure Systems LLC, a small disadvantaged business located in Newton, MA. The contract is for the development of "Vector-Based Delivery of HIV Broadly Neutralizing Antibodies" and is related to NIAID's SBIR program objectives to stimulate technological...
- This is a $599,914 firm-fixed-price contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), part of the U.S. Department of Health and Human Services, to Antagen Biosciences Inc. (doing business as Antagen Pharmaceuticals), a small disadvantaged and minority-owned biotechnology company. The objective of this SBIR Phase I research contract is to develop a nanoparticle-based vaccine delivery platform to induce broadly neutralizing antibodies against HIV. The work will...
- This federal contract award, valued at $2,959,434.41, was issued by the National Institute of Allergy and Infectious Diseases (NIAID), a component of the U.S. Department of Health and Human Services, to Advanced Bioscience Laboratories, Inc. (ABL). The contract is for the synthesis and production of an HIV-1 envelope glycopeptide immunogen nanoparticle vaccine as part of NIAID's Preclinical Development Support program. This is a cost-plus-fixed-fee delivery order contract with an ultimate...
- This is a $9,545,732.00 cost-plus-fixed-fee delivery order contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a civilian agency within the Department of Health and Human Services, to Advanced Bioscience Laboratories, Inc. (ABL), a for-profit manufacturer of goods. The contract is for the production of cGMP native flexibly linked HIV-1 envelope protein to support NIAID's preclinical development efforts. This contract is not set aside and is part of a larger $24...
- This is a $599,061 Small Business Innovation Research (SBIR) Phase I contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH) within the Department of Health and Human Services (HHS). The purpose is to develop imprinted polymer resins for purifying HIV envelope vaccine candidates. The prime contractor is Zymeron Corporation, a minority-owned small business biotechnology company located in Research Triangle Park,...
- This federal contract award was issued by the National Institute of Allergy and Infectious Diseases (NIAID), a civilian agency under the Department of Health and Human Services. The contract, valued at $3,731,476.00, is for the NIAID Preclinical Development Support program, specifically to support the production and testing of ADC6-HIV GP140 and ADC7-HIV GP140. The prime contractor is Advanced Bioscience Laboratories, Inc. (ABL), a for-profit manufacturer of goods that specializes in the...
- This is a Small Business Innovation Research (SBIR) Phase I contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a component of the National Institutes of Health (NIH), to Acousticabio, Inc., a small business in Cambridge, MA. The contract, valued at $295,116, is for the development of "HIGH-DOSE AND SUSTAINED DELIVERY OF HIV-1 BROADLY NEUTRALIZING ANTIBODIES VIA SUBCUTANEOUS INJECTION OF HYDROGEL-BASED MICROPARTICLE FORMATIONS". This contract is...